Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Surge Therapeutics Inc. currently manages a portfolio within the Biotechnology & Pharmaceuticals technology area. The company is responding to 2 pending office actions. This indicates a moderate level of current activity as the firm seeks to secure its intellectual property rights.
The prosecution landscape for this company involves 2 distinct examiners and 2 distinct art units. This direct correlation between the number of examiners and art units suggests that each pending application is being handled in a different specialized department. With 2 distinct examiners, the company must tailor its legal arguments to two different individuals who may have varying interpretations of the prior art.
YANG, TIAN is identified as the busiest examiner for the portfolio. This examiner is currently overseeing 1 busiest examiner pending office action. While YANG, TIAN is the busiest, they do not handle all of the 2 pending office actions. This split workload means that the company's success is distributed across the 2 distinct examiners currently reviewing the applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YANG, TIAN | 1 | — | — |
| POPA, ILEANA | 1 | 21.7% | +15.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021634 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | POPA, ILEANA | 26d overdue |
| 18274754 | CANCER THERAPY | YANG, TIAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021634 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | POPA, ILEANA | 26d overdue |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18274754 | CANCER THERAPY | YANG, TIAN | 1674 | §103§112 | Non-Final OA | — | Pending | Jul 28, 2023 |
| 18021634 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | POPA, ILEANA | 1633 | §103§112Other | Final Rejection | 26d overdue | Pending | Feb 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSurge Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Tian Yang has the most, with 1 of Surge Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
